MedTrace Logo

A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With Solid Tumors

NCT07703878 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 302

Last updated 2026-08-10

No results posted yet for this study

Summary

The goal of this clinical study is to learn more about the study drug GS-1206, including its safety, tolerability, and antitumor activity in adult participants with solid tumors.

Conditions

Interventions

DRUG

GS-1206

Administered Orally

Sponsors & Collaborators

Principal Investigators

  • Gilead Study Director · Gilead Sciences

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-17
Primary Completion
2029-09-30
Completion
2029-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07703878 on ClinicalTrials.gov